Back to Search
JAMES FRESTON, M.D.
M.D.
Gastroenterology Physician
NPI: 1184629875Individual
Specialties, Licenses & Credentials
Research & Publications (20)
The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis.
PMID 19416133·Aliment Pharmacol Ther·2009
4-observational
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
PMID 15478848·Am J Med·2004
4-observational
A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
PMID 15298634·Aliment Pharmacol Ther·2004
3-trial
Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
PMID 15142201·Aliment Pharmacol Ther·2004
3-trial
Review article: approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy?
PMID 14725577·Aliment Pharmacol Ther·2004
6-review
Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
PMID 12562448·Aliment Pharmacol Ther·2003
3-trial
Motion - All patients with GERD should be offered once in a lifetime endoscopy: arguments against the motion.
PMID 12226684·Can J Gastroenterol·2002
8-other
Antagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy?
PMID 11600461·Gut·2001
6-review
Review article: role of proton pump inhibitors in non-H. pylori-related ulcers.
PMID 11556873·Aliment Pharmacol Ther·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 263 FARMINGTON AVE
FARMINGTON, CT 06030 - Phone
- (860) 679-3238
Quick Facts
- NPI
- 1184629875
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile